Monthly
US$200
Billed every month
Norepinephrine Bitartrate Injection(重酒石酸去甲肾上腺素注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders34View records ↓
Under-review filings9View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers42View records ↓
API companies with A status20View records ↓
Chemical-drug catalogue
Loaded records: 34 holders; 5 in the quality-and-efficacy consistency-evaluation category, and 26 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 江苏润恒制药有限公司 | 江苏润恒制药有限公司 | 国药准字H20266050 | 2026/09/22 | 1ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏润恒制药有限公司 | 江苏润恒制药有限公司 | 国药准字H20266051 | 2026/09/22 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南龙海天然植物药业有限公司 | 云南龙海天然植物药业有限公司 | 国药准字H20265991 | 2026/09/15 | 4ml：8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山西振东泰盛制药有限公司 | 山西振东泰盛制药有限公司 | 国药准字H20265662 | 2026/08/18 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州白云山明兴制药有限公司 | 广州白云山明兴制药有限公司 | 国药准字H44022396 | 2026/08/17 | 1ml：2mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 浙江尚科生物医药有限公司 | 浙江尚科生物医药有限公司 | 国药准字H20265272 | 2026/07/21 | 4ml：8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西人可医药科技有限公司 | 津药和平（天津）制药有限公司 | 国药准字H20264332 | 2026/05/12 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江西人可医药科技有限公司 | 津药和平（天津）制药有限公司 | 国药准字H20264331 | 2026/05/12 | 1ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南药科院生物医药股份有限公司 | 楚雄和创药业有限责任公司 | 国药准字H20263643 | 2026/03/17 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江博崤生物制药有限公司 | 浙江博崤生物制药有限公司 | 国药准字H20263078 | 2026/01/14 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 锦州奥鸿药业有限责任公司 | 锦州奥鸿药业有限责任公司 | 国药准字H20263119 | 2026/01/14 | 4ml：8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南华纳大药厂股份有限公司 | 湖南华纳大药厂股份有限公司 | 国药准字H20256386 | 2025/12/22 | 4ml：8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南爱科制药有限公司 | 海南爱科制药有限公司 | 国药准字H20256126 | 2025/12/03 | 1ml:2mg | Not stated by source | CDE |
| 江西泰吉立生物医药科技有限公司 | 江西银涛药业股份有限公司 | 国药准字H20256132 | 2025/12/03 | 4ml:8mg | Not stated by source | CDE |
| 遂成药业股份有限公司 | 遂成药业股份有限公司 | 国药准字H20256104 | 2025/12/03 | 4ml:8mg | Not stated by source | CDE |
| 西安利君制药有限责任公司 | 西安利君制药有限责任公司 | 国药准字H61021666 | 2025/10/31 | 1ml:2mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 中山万汉制药有限公司 | 中山万汉制药有限公司 | 国药准字H20255319 | 2025/09/02 | 4ml: 8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宜昌人福药业有限责任公司 | 宜昌人福药业有限责任公司 | 国药准字H20255191 | 2025/08/26 | 4ml：8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 嘉实（湖南）医药科技有限公司 | 湖南五洲通药业股份有限公司 | 国药准字H20255142 | 2025/08/19 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 嘉实（湖南）医药科技有限公司 | 湖南五洲通药业股份有限公司 | 国药准字H20255141 | 2025/08/19 | 1ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏江丰医药科技有限公司 | 江苏吴中医药集团有限公司苏州制药厂 | 国药准字H20254192 | 2025/05/20 | 4ml：8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海禾丰制药有限公司 | 上海禾丰制药有限公司 | 国药准字H31021177 | 2025/05/14 | 1ml:2mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 中润药业有限公司 | 成都市海通药业有限公司 | 国药准字H20254158 | 2025/05/13 | 1ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中润药业有限公司 | 成都市海通药业有限公司 | 国药准字H20254159 | 2025/05/13 | 4ml：8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏联环药业股份有限公司 | 江苏联环药业股份有限公司 | 国药准字H20254039 | 2025/04/30 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州瑞尔医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20258042 | 2025/03/25 | 1ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 武汉久安药业有限公司 | 朗天药业（湖北）有限公司 | 国药准字H20249676 | 2024/12/01 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥国药诺和药业有限公司 | 国药集团国瑞药业有限公司 | 国药准字H20249337 | 2024/11/15 | 1ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥国药诺和药业有限公司 | 国药集团国瑞药业有限公司 | 国药准字H20249338 | 2024/11/15 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天方药业有限公司 | 天方药业有限公司 | 国药准字H20249334 | 2024/11/15 | 4ml∶8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 福安药业集团庆余堂制药有限公司 | 福安药业集团庆余堂制药有限公司 | 国药准字H20244996 | 2024/09/26 | 1ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州瑞尔医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20244852 | 2024/09/10 | 4ml：8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H20244708 | 2024/08/20 | 4ml：4mg（以去甲肾上腺素计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南倍特药业有限公司 | 海南倍特药业有限公司 | 国药准字H20244336 | 2024/06/28 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南倍特药业有限公司 | 海南倍特药业有限公司 | 国药准字H20244335 | 2024/06/28 | 1ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都欣捷高新技术开发股份有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20243327 | 2024/03/12 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都欣捷高新技术开发股份有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20243326 | 2024/03/12 | 1ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海葆隆生物科技有限公司 | 亚邦医药股份有限公司 | 国药准字H20234738 | 2023/12/29 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都硕德药业有限公司 | 成都硕德药业有限公司 | 国药准字H20234333 | 2023/10/18 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥亿帆生物制药有限公司 | 合肥亿帆生物制药有限公司 | 国药准字H20233307 | 2023/03/21 | 4ml:8mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 天津金耀药业有限公司 | 天津金耀药业有限公司 | 国药准字H12020621 | 2021/10/22 | 1ml：2mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 远大医药（中国）有限公司 | 远大医药（中国）有限公司 | 国药准字H20217065 | 2021/07/30 | 4ml:8mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 远大医药（中国）有限公司 | 远大医药（中国）有限公司 | 国药准字H42021301 | 2021/07/30 | 1ml:2mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 上海禾丰制药有限公司 | 上海禾丰制药有限公司 | 国药准字H20247024 | 2024/02/05 | 4ml：8mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 42 distinct approval numbers and 30 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广州白云山明兴制药有限公司 | 国药准字H44022396 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010100375 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H31021177 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010100673 | NHSA |
| 津药和平(天津)制药有限公司 | 国药准字H12020621 | 1ml∶2mg | Category A (甲) | XC01CAQ120B002010100874 | NHSA |
| 锦州奥鸿药业有限责任公司 | 国药准字H20263119 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010101190 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20254039 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010101467 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20244996 | 1ml∶2mg | Category A (甲) | XC01CAQ120B002010101877 | NHSA |
| 武汉久安药业有限公司 | 国药准字H20249676 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010101949 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H42021301 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010101984 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61021666 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010102503 | NHSA |
| 石家庄四药有限公司 | 国药准字H20244708 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010102763 | NHSA |
| 天方药业有限公司 | 国药准字H20249334 | 4ml∶8mg | Category A (甲) | XC01CAQ120B002010103098 | NHSA |
| 遂成药业股份有限公司 | 国药准字H20256104 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010103204 | NHSA |
| 海南爱科制药有限公司 | 国药准字H20256126 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010105759 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20244335 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010105791 | NHSA |
| 云南龙海天然植物药业有限公司 | 国药准字H20265991 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010106286 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20255319 | 4ml: 8mg | Category A (甲) | XC01CAQ120B002010109920 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20233307 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010182719 | NHSA |
| 上海葆隆生物科技有限公司 | 国药准字H20234738 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010183069 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20243326 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010183325 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20244852 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010183450 | NHSA |
| 合肥国药诺和药业有限公司 | 国药准字H20249337 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010183719 | NHSA |
| 江苏江丰医药科技有限公司 | 国药准字H20254192 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010183817 | NHSA |
| 成都硕德药业有限公司 | 国药准字H20234333 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010183830 | NHSA |
| 江西人可医药科技有限公司 | 国药准字H20264331 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010184300 | NHSA |
| 云南药科院生物医药股份有限公司 | 国药准字H20263643 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010184547 | NHSA |
| 江西泰吉立生物医药科技有限公司 | 国药准字H20256132 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010184945 | NHSA |
| 广州惠沣德生物技术有限公司 | 国药准字H20256284 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010185110 | NHSA |
| 浙江尚科生物医药有限公司 | 国药准字H20265272 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010185772 | NHSA |
| 广州白云山明兴制药有限公司 | 国药准字H44022396 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010200375 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H31021177 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010200673 | NHSA |
| 津药和平(天津)制药有限公司 | 国药准字H12020621 | 1ml∶2mg | Category A (甲) | XC01CAQ120B002010200874 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H20254039 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010201467 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20244996 | 1ml∶2mg | Category A (甲) | XC01CAQ120B002010201877 | NHSA |
| 武汉久安药业有限公司 | 国药准字H20249676 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010201949 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H42021301 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010201984 | NHSA |
| 石家庄四药有限公司 | 国药准字H20244708 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010202763 | NHSA |
| 天方药业有限公司 | 国药准字H20249334 | 4ml∶8mg | Category A (甲) | XC01CAQ120B002010203098 | NHSA |
| 遂成药业股份有限公司 | 国药准字H20256104 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010203204 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20244335 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010205791 | NHSA |
| 云南龙海天然植物药业有限公司 | 国药准字H20265991 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010206286 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20233307 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010282719 | NHSA |
| 上海葆隆生物科技有限公司 | 国药准字H20234738 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010283069 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20243326 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010283325 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20244852 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010283450 | NHSA |
| 合肥国药诺和药业有限公司 | 国药准字H20249337 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010283719 | NHSA |
| 江苏江丰医药科技有限公司 | 国药准字H20254192 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010283817 | NHSA |
| 成都硕德药业有限公司 | 国药准字H20234333 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010283830 | NHSA |
| 云南药科院生物医药股份有限公司 | 国药准字H20263643 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010284547 | NHSA |
| 广州惠沣德生物技术有限公司 | 国药准字H20256284 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010285110 | NHSA |
| 浙江尚科生物医药有限公司 | 国药准字H20265272 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010285772 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H31021177 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010300673 | NHSA |
| 津药和平(天津)制药有限公司 | 国药准字H12020621 | 1ml∶2mg | Category A (甲) | XC01CAQ120B002010300874 | NHSA |
| 福安药业集团庆余堂制药有限公司 | 国药准字H20244996 | 1ml∶2mg | Category A (甲) | XC01CAQ120B002010301877 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H42021301 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010301984 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20244335 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010305791 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20233307 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010382719 | NHSA |
| 上海葆隆生物科技有限公司 | 国药准字H20234738 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010383069 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20244852 | 4ml:8mg | Category A (甲) | XC01CAQ120B002010383450 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H31021176 | 2ml:10mg | Category A (甲) | XC01CAQ120B002020100673 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H20217065 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020101984 | NHSA |
| 西安利君制药有限责任公司 | 国药准字H61021666 | 1ml:2mg | Category A (甲) | XC01CAQ120B002020102503 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H37020634 | 2ml:10mg | Category A (甲) | XC01CAQ120B002020104187 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20244336 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020105791 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20247146 | 1ml: 2mg | Category A (甲) | XC01CAQ120B002020182719 | NHSA |
| 上海葆隆生物科技有限公司 | 国药准字H20269012 | 1ml:2mg | Category A (甲) | XC01CAQ120B002020183069 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20243327 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020183325 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20258042 | 1ml:2mg | Category A (甲) | XC01CAQ120B002020183450 | NHSA |
| 合肥国药诺和药业有限公司 | 国药准字H20249338 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020183719 | NHSA |
| 江西人可医药科技有限公司 | 国药准字H20264332 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020184300 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H37020634 | 2ml:10mg | Category A (甲) | XC01CAQ120B002020204187 | NHSA |
| 海南倍特药业有限公司 | 国药准字H20244336 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020205791 | NHSA |
| 上海葆隆生物科技有限公司 | 国药准字H20269012 | 1ml:2mg | Category A (甲) | XC01CAQ120B002020283069 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20243327 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020283325 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H20217065 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020283383 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20258042 | 1ml:2mg | Category A (甲) | XC01CAQ120B002020283450 | NHSA |
| 合肥国药诺和药业有限公司 | 国药准字H20249338 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020283719 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H20247024 | 4ml:8mg | Category A (甲) | XC01CAQ120B002030100673 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H42022048 | 2ml:10mg | Category A (甲) | XC01CAQ120B002030101984 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H20247024 | 4ml:8mg | Category A (甲) | XC01CAQ120B002030200673 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H42022048 | 2ml:10mg | Category A (甲) | XC01CAQ120B002030201984 | NHSA |
| 远大医药(中国)有限公司 | 国药准字H42022048 | 2ml:10mg | Category A (甲) | XC01CAQ120B002030301984 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20266050 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010185560 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20266050 | 1ml:2mg | Category A (甲) | XC01CAQ120B002010285560 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20266051 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020185560 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20266051 | 4ml:8mg | Category A (甲) | XC01CAQ120B002020285560 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 9 filings and 7 distinct first applicants.
Generic 8 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 绪必迪药业（沧州）有限公司 | CYHS2602391 | Generic | 2026/09/23 | Not stated by source | CDE |
| 石家庄四药有限公司 | CYHB2601445 | Supplement | 2026/07/28 | Not stated by source | CDE |
| 河北科源药业有限公司;河北仁合益康药业有限公司 | CYHS2600955 | Generic | 2026/04/24 | Not stated by source | CDE |
| 四川益生智同医药生物科技发展有限公司;成都市海通药业有限公司 | CYHS2504204 | Generic | 2025/12/06 | Not stated by source | CDE |
| 四川益生智同医药生物科技发展有限公司;成都市海通药业有限公司 | CYHS2504203 | Generic | 2025/12/06 | Not stated by source | CDE |
| 山西阳和医药技术有限公司;山西普恒制药有限公司 | CYHS2504126 | Generic | 2025/12/02 | Not stated by source | CDE |
| 山西阳和医药技术有限公司;山西普恒制药有限公司 | CYHS2504125 | Generic | 2025/12/02 | Not stated by source | CDE |
| 辰欣药业股份有限公司 | CYHS2503325 | Generic | 2025/09/08 | Not stated by source | CDE |
| 广东南国药业有限公司 | CYHS2502844 | Generic | 2025/08/06 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
API registrations
Non-component matches: 20 companies with A status and 4 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 重酒石酸去甲肾上腺素 | 山东辰龙药业有限公司 | Y20260000628 | I | Exact ingredient | 2026/07/23 | CDE |
| 重酒石酸去甲肾上腺素 | 绪必迪药业（沧州）有限公司 | Y20250001092 | I | Exact ingredient | 2025/10/20 | CDE |
| 重酒石酸去甲肾上腺素 | 植恩生物技术股份有限公司 | Y20250001057 | I | Exact ingredient | 2025/10/15 | CDE |
| 重酒石酸去甲肾上腺素 | 山西振东泰盛制药有限公司 | Y20240001074 | A | Exact ingredient | 2026/07/13 | CDE |
| 重酒石酸去甲肾上腺素 | 浙江尚泰生物制药有限公司 | Y20240000586 | A | Exact ingredient | 2026/09/19 | CDE |
| 重酒石酸去甲肾上腺素 | 湖南华纳大药厂手性药物有限公司 | Y20240000250 | A | Exact ingredient | 2025/10/22 | CDE |
| 重酒石酸去甲肾上腺素 | 锦州奥鸿药业有限责任公司 | Y20240000355 | A | Exact ingredient | 2026/11/05 | CDE |
| 重酒石酸去甲肾上腺素 | 浙江博崤生物制药有限公司 | Y20240000258 | A | Exact ingredient | 2025/12/18 | CDE |
| 重酒石酸去甲肾上腺素 | 河北创健药业有限公司 | Y20230000508 | A | Exact ingredient | 2025/02/12 | CDE |
| 重酒石酸去甲肾上腺素 | 安徽美诺华药物化学有限公司 | Y20230000869 | A | Exact ingredient | 2026/01/01 | CDE |
| 重酒石酸去甲肾上腺素 | 中山万汉制药有限公司 | Y20230000665 | A | Exact ingredient | 2025/08/02 | CDE |
| 重酒石酸去甲肾上腺素 | 博瑞制药（苏州）有限公司 | Y20230000409 | A | Exact ingredient | 2024/11/29 | CDE |
| 重酒石酸去甲肾上腺素 | 上海现代哈森（商丘）药业有限公司 | Y20230000575 | A | Exact ingredient | 2025/02/07 | CDE |
| 重酒石酸去甲肾上腺素 | 海南卓科制药有限公司 | Y20220001319 | A | Exact ingredient | 2024/07/17 | CDE |
| 重酒石酸去甲肾上腺素 | 天方药业有限公司 | Y20220001149 | A | Exact ingredient | 2025/05/20 | CDE |
| 重酒石酸去甲肾上腺素 | 河北广祥制药有限公司 | Y20220000836 | A | Exact ingredient | 2024/04/13 | CDE |
| 重酒石酸去甲肾上腺素 | 成都新恒创药业有限公司 | Y20220000724 | A | Exact ingredient | 2026/01/22 | CDE |
| 重酒石酸去甲肾上腺素 | 深圳沃兰德药业有限公司 | Y20220000298 | I | Exact ingredient | 2023/12/26 | CDE |
| 重酒石酸去甲肾上腺素 | 湖北美林药业有限公司 | Y20220000243 | A | Exact ingredient | 2024/02/29 | CDE |
| 重酒石酸去甲肾上腺素 | 四川青木制药有限公司 | Y20210001069 | A | Exact ingredient | 2025/01/25 | CDE |
| 重酒石酸去甲肾上腺素 | 宿州亿帆药业有限公司 | Y20210000170 | A | Exact ingredient | 2024/05/21 | CDE |
| 重酒石酸去甲肾上腺素 | ChemPacific Corp | Y20200000850 | A | Exact ingredient | 2023/07/04 | CDE |
| 重酒石酸去甲肾上腺素 | 武汉武药制药有限公司 | Y20190009540 | A | Exact ingredient | 2025/06/17 | CDE |
| 重酒石酸去甲肾上腺素 | 山西振东泰盛制药有限公司 | Y20190006135 | A | Exact ingredient | 2025/11/04 | CDE |
| 重酒石酸去甲肾上腺素 | Cambrex Profarmaco Milano S.r.l. | Y20180000333 | A | Exact ingredient | 2024/08/07 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/09/23Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Norepinephrine Bitartrate Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy